CMA narrows AkzoNobel-Axalta concerns to UK refinish, testing a one-remedy playbook

What happened

The UK Competition and Markets Authority has raised concerns in its Phase 1 review of the AkzoNobel-Axalta merger. It found problems only in the supply of vehicle refinish coatings in the UK. The companies plan to offer the divestment they have already agreed with the European Commission.

The deal is a coatings transaction, not a pharma one, but the sequence is instructive for any M&A team. A regulator identified a narrow overlap, and the parties responded by proposing a remedy already settled with another authority. The material provided does not give the scope or buyer of the divestment, deal value, or the timetable for the CMA's next decision, so we do not speculate on them.

The logic of a single, portable remedy

The most important detail is what the CMA did not find. Its concerns are limited to one UK product market, which suggests the merger's overall rationale is not under challenge. The issue is a localised overlap, and localised overlaps can often be cured by carving out the business that causes them.

The parties' choice to offer the EC-agreed divestment is also strategically efficient. Reusing one remedy across jurisdictions reduces the risk of conflicting conditions, avoids building a separate package for each authority, and signals that the merging companies see the overlap as one problem with one fix. Whether the CMA accepts that the EC remedy fully addresses a UK-specific market is the open question. The UK finding concerns UK supply, so the remedy's adequacy will be judged against UK conditions.

Read-across for pharma deal teams

Pharma M&A faces the same structural issue. Acquirers with overlapping products in a single indication or territory often find that antitrust risk sits in a few narrow markets rather than across the whole deal. The AkzoNobel-Axalta case reinforces the value of mapping those pockets early and settling on a divestment strategy before regulators raise them.

Other transactions in today's news flow show how varied deal structures are, and how different their regulatory exposure is. Silence Therapeutics reported a $12.4M third-quarter loss and $247.7M in cash while its acquisition by Merck KGaA is pending. Alcon, which reported third-quarter sales up 5% to $2.7bn, highlighted its planned purchase of Neurotech Pharmaceuticals. Both are acquisitions that must still cross the finish line, though the material says nothing about their regulatory review.

The other end of the deal spectrum

Most of the day's other deals avoid merger control entirely. Gedeon Richter has licensed estetrol combination rights to Eli Lilly worldwide, covering women's health and cardiometabolic disease. The deal includes a US co-commercialisation option on Richter's FYLREVY and Lilly's purchase of about $15M of Richter shares. Kiora has acquired rights outside Asia to Senju's oral calpain inhibitor KIO-401 (mitucapistat) for retinal artery occlusion, and has asked the FDA for a pre-IND meeting and orphan drug designation. Colospan, an Eocene subsidiary, granted Hospital Line SA exclusive rights to market the CE-marked CG-100 bypass device in Greece and Cyprus.

Licences, options and distribution agreements let companies access assets without triggering the competition scrutiny that full mergers attract. They are also the usual way smaller companies exit or monetise programmes. Theriva Biologics sold its SYN-004 antibiotic-enzyme assets to Biossil Labs for $350,000 upfront. Longeveron started a strategic alternatives review, weighing a sale or merger, after laromestrocel missed its primary endpoint in the ELPIS II trial in infants with hypoplastic left heart syndrome. The contrast with the AkzoNobel-Axalta process is stark: for distressed or small-cap assets the question is whether a buyer exists, while for large mergers it is whether regulators will let the combination proceed intact.

Risks

For AkzoNobel and Axalta, the main risk is that the CMA finds the proposed remedy insufficient for the UK market, or that its scrutiny extends the timetable. The material gives no basis for judging either likelihood. A second risk is that a remedy tailored to one authority's concerns may not map neatly onto another's, even when the product market is the same.

More broadly, the divestment-reuse approach depends on there being a credible buyer and a separable business. Those conditions are not guaranteed in every sector, and they are harder to meet when overlaps involve shared manufacturing or intertwined development programmes.

What to watch

Watch whether the CMA accepts the EC-agreed divestment as adequate for UK vehicle refinish coatings, and how it communicates the next procedural step. Also watch for any detail on the divestment's scope and buyer.

For pharma, watch how the pending Silence and Neurotech transactions progress, and whether Longeveron's review ends in a sale or merger.